CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

View Poster

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

View PDF

Multifunctional Humabody® biologics for immune-oncology, based on in vivo matured fully human VH domains

Multifunctional Humabody® biologics for immune-oncology, based on in vivo matured fully human VH
domains (PEGS 2018 poster)

View Poster

Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018

Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018

View PDF

Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic

Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO
partner, as it advances towards the clinic

View PDF